Abstract
Background:
Granulocyte colony stimulating factor (G-CSF) safely stimulates the production of neutrophils in normal people and neutropenic patients. Phase II studies have been completed that explored the role of G-CSF in either abrogating or accelerating recovery from chemotherapy-induced neutropenia.
Methods:
Fourteen patients with resistant/relapsed high-grade non-Hodgkin's lymphoma were treated with a dexamethasone, cytarabine and cisplatin (DHAP) regimen, and with G-CSF between chemotherapeutic courses.
Results:
All patients showed a rise in neutrophil count; none was neutropenic when hospitalized for subsequent DHAP courses. Furthermore, the interval between cycles was decreased in 11 of the 14 patients. The overall response rate was 86%, with 4 patients obtaining complete remission.
Conclusions:
Administration of G-CSF was associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection and to maintain planned chemotherapy doses.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Dexamethasone / administration & dosage
-
Dexamethasone / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Neutropenia / chemically induced
-
Neutropenia / therapy*
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Recombinant Proteins / therapeutic use
-
Remission Induction
-
Treatment Outcome
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Immunologic Factors
-
Recombinant Proteins
-
Cytarabine
-
Bleomycin
-
Granulocyte Colony-Stimulating Factor
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Leucovorin
-
Fluorouracil
-
Prednisone
-
Methotrexate
Supplementary concepts
-
DHAP protocol
-
F-MACHOP protocol
-
MACOP-B protocol